Received: 11 January 2022
Accepted: 24 August 2022
First Online: 17 September 2022
: The trial was conducted at the UMASS Chan Neurology dementia clinic in accordance with the principles of Good Clinical Practice guidelines and approved by the UMASS Medical School institutional review board according to their ethical standards for human research. Written informed consent was provided by the subjects or their legal representatives.
: None required.
: The authors report no relevant conflicts of interest. Dr. Shazeeb reports consulting fees (Sanofi) and research support (Sio Gene Therapies, Inozyme, the National Institutes of Health (NIH), Gilbert Foundation, and Massachusetts Life Science Center) outside the submitted work. Dr. Gounis reports consulting fees (Astrocyte Pharmaceuticals, Cerenovous, Imperative Care, Medtronic Neurovascular, Mivi Neurosciences, Phenox, Q’Apel, Route 92 Medical, Stryker Neurovascular, and Wallaby Medical; holds stock in Galaxy Medical, Imperative Care, InNeuroCo and Neurogami) and research support (NIH, United States – Israel Binational Science Foundation, Anaconda, ApicBio, Arsenal Medical, Axovant, Cerenovus, Ceretrieve, Cook Medical, Galaxy Therapeutics, Gentuity, Imperative Care, InNeuroCo, Insera, Magneto, Microvention, Medtronic Neurovascular, MIVI Neurosciences, Naglreiter MDDO, Neurogami, Omniox, Philips Healthcare, Rapid Medical, Route 92 Medical, Stryker Neurovascular, Syntheon, ThrombX Medical and the Wyss Institute) outside of the submitted work. Dr. Henninger reports consulting fees (Astrocyte Pharmaceuticals) and research support (Department of Defense's Congressionally Directed Medical Research Programs, Focalcool, and Omniox) outside of the submitted work.